Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

Role of interleukin-1 inhibitors in osteoarthritis: an evidence-based review.

Jotanovic Z, Mihelic R, Sestan B, Dembic Z.

Drugs Aging. 2012 May 1;29(5):343-58. doi: 10.2165/11599350-000000000-00000. Review.

PMID:
22550965
2.

Anticytokine therapy for osteoarthritis: evidence to date.

Malemud CJ.

Drugs Aging. 2010 Feb 1;27(2):95-115. doi: 10.2165/11319950-000000000-00000.

PMID:
20104937
3.

The role of cytokines in osteoarthritis pathophysiology.

Fernandes JC, Martel-Pelletier J, Pelletier JP.

Biorheology. 2002;39(1-2):237-46. Review.

PMID:
12082286
4.

The association of peripheral monocyte derived interleukin 1beta (IL-1beta), IL-1 receptor antagonist, and tumor necrosis factor-alpha with osteoarthritis in the elderly.

Fraenkel L, Roubenoff R, LaValley M, McAlindon T, Chaisson C, Evans S, Harris T, Dinarello CA, Felson DT.

J Rheumatol. 1998 Sep;25(9):1820-6.

PMID:
9733466
5.
6.

Interleukin-1beta induced activation of nuclear factor-kappab can be inhibited by novel pharmacological agents in osteoarthritis.

Lauder SN, Carty SM, Carpenter CE, Hill RJ, Talamas F, Bondeson J, Brennan P, Williams AS.

Rheumatology (Oxford). 2007 May;46(5):752-8. Epub 2007 Jan 11.

PMID:
17218328
7.

[Targeted anti-cytokine therapies for osteoarthritis].

Chevalier X, Mugnier B, Bouvenot G.

Bull Acad Natl Med. 2006 Oct;190(7):1411-20; discussion 1420, 1475-7. Review. French.

PMID:
17450677
8.

Anticytokine therapy for osteoarthritis.

Goldring MB.

Expert Opin Biol Ther. 2001 Sep;1(5):817-29. Review.

PMID:
11728217
9.

Osteoarthritis: can anti-cytokine therapy play a role in treatment?

Calich AL, Domiciano DS, Fuller R.

Clin Rheumatol. 2010 May;29(5):451-5. doi: 10.1007/s10067-009-1352-3. Epub 2010 Jan 27. Review.

PMID:
20108016
10.

Osteoarthritis gene therapy.

Evans CH, Gouze JN, Gouze E, Robbins PD, Ghivizzani SC.

Gene Ther. 2004 Feb;11(4):379-89. Review.

PMID:
14724685
11.

Reversal of autocrine and paracrine effects of interleukin 1 (IL-1) in human arthritis by type II IL-1 decoy receptor. Potential for pharmacological intervention.

Attur MG, Dave M, Cipolletta C, Kang P, Goldring MB, Patel IR, Abramson SB, Amin AR.

J Biol Chem. 2000 Dec 22;275(51):40307-15.

12.
13.

Emerging pathways and promising agents with possible disease modifying effect in osteoarthritis treatment.

Jotanovic Z, Mihelic R, Sestan B, Dembic Z.

Curr Drug Targets. 2014 Jun;15(6):635-61.

PMID:
24597569
14.

[Importance of interleukin-I receptors in osteoarthritis].

Martel-Pelletier J, Pelletier JP.

Rev Rhum Ed Fr. 1994 Nov 15;61(9 Pt 2):109S-113S. Review. French.

PMID:
7858606
15.

Role of proinflammatory cytokines in the pathophysiology of osteoarthritis.

Kapoor M, Martel-Pelletier J, Lajeunesse D, Pelletier JP, Fahmi H.

Nat Rev Rheumatol. 2011 Jan;7(1):33-42. doi: 10.1038/nrrheum.2010.196. Epub 2010 Nov 30. Review.

PMID:
21119608
16.

OA clinical trials: current targets and trials for OA. Choosing molecular targets: what have we learned and where we are headed?

Hellio Le Graverand-Gastineau MP.

Osteoarthritis Cartilage. 2009 Nov;17(11):1393-401. doi: 10.1016/j.joca.2009.04.009. Epub 2009 Apr 22. Review.

17.
18.
19.

New horizons in osteoarthritis.

Oliviero F, Ramonda R, Punzi L.

Swiss Med Wkly. 2010 Sep 17;140:w13098. doi: 10.4414/smw.2010.13098. eCollection 2010. Review.

PMID:
20458653
20.

In vitro effects of diacerhein and rhein on interleukin 1 and tumor necrosis factor-alpha systems in human osteoarthritic synovium and chondrocytes.

Martel-Pelletier J, Mineau F, Jolicoeur FC, Cloutier JM, Pelletier JP.

J Rheumatol. 1998 Apr;25(4):753-62.

PMID:
9558181

Supplemental Content

Support Center